RAGE, glomerulosclerosis and proteinuria: Roles in podocytes and endothelial cells

Trends in Endocrinology and Metabolism

Volumn 21, Issue 1, 2010, Pages 50-56

  D'Agati, Vivette ^a   Yan, Shi Fang ^a   Ramasamy, Ravichandran ^a   Schmidt, Ann Marie ^a  

^a Columbia University ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADVANCED GLYCATION END PRODUCT RECEPTOR; SOLUBLE ADVANCED GLYCATION END PRODUCT RECEPTOR; UNCLASSIFIED DRUG;

DIABETIC NEPHROPATHY; DISEASE MODEL; ENDOTHELIUM CELL; EXPERIMENTAL MOUSE; GENE EXPRESSION; GENETIC POLYMORPHISM; GLOMERULOSCLEROSIS; HOMEOSTASIS; HUMAN; LUPUS ERYTHEMATOSUS NEPHRITIS; NONHUMAN; PATHOGENESIS; PODOCYTE; PRIORITY JOURNAL; PROTEINURIA; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; DIABETIC NEPHROPATHIES; ENDOTHELIAL CELLS; HUMANS; KIDNEY DISEASES; MICE; PODOCYTES; POLYMORPHISM, GENETIC; PROTEINURIA; RECEPTORS, IMMUNOLOGIC;

EID: 73249122895     PISSN: 10432760     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tem.2009.07.003     Document Type: Review

References (70)

1. Chang J.S., et al. Oxygen deprivation triggers upregulation of early growth response-1 by the receptor for advanced glycation end products. Circ. Res. 102 (2008) 905-913
2. Bucciarelli L.G., et al. RAGE and modulation of ischemic injury in the diabetic myocardium. Diabetes 57 (2008) 1941-1951
3. Sourris K.C., and Forbes J.M. Interactions between advanced glycation end-products (AGE) and their receptors in the development and progression of diabetic nephropathy - are these receptors valid therapeutic targets. Curr. Drug Targets 10 (2009) 42-50
4. Guo Z.J., et al. Advanced oxidation protein products activate vascular endothelial cells via a RAGE-mediated signaling pathway. Antioxid. Redox Signal. 10 (2008) 1699-1712
5. -/- mice. J. Clin. Invest. 118 (2008) 183-194
6. Iacobini C., et al. Advanced lipoxidation end-products mediate lipid-induced glomerular injury: role of receptor-mediated mechanisms. J. Pathol. 218 (2009) 360-369
7. Guo J., et al. RAGE mediates podocyte injury in adriamycin-induced glomerulosclerosis. J. Am. Soc. Nephrol. 19 (2008) 961-972
8. Yan S.F., et al. Tempering the wrath of RAGE: an emerging therapeutic strategy against diabetic complications, neurodegeneration and inflammation. Ann. Med. 25 (2009) 1-15
9. Nishi S., et al. New advances in renal amyloidosis. Clin. Exp. Nephrol. 12 (2008) 93-101
10. Yan S.F., et al. Receptor for AGE (RAGE) and its ligands-cast into leading roles in diabetes and the inflammatory response. J. Mol. Med. 87 (2009) 235-247
11. Tanji N., et al. Expression of advanced glycation end products and their cellular receptor RAGE in diabetic nephropathy and nondiabetic renal disease. J. Am. Soc. Nephrol. 11 (2000) 1656-1666
12. Morcos M., et al. Activation of tubular epithelial cells in diabetic nephropathy. Diabetes 51 (2002) 3532-3544
13. Berrou J., et al. Advanced glycation end products regulate extracellular matrix protein and protease expression by human glomerular mesangial cells. Int. J. Mol. Med. 23 (2009) 513-520
14. Gu L., et al. Role of receptor for advanced glycation endproducts and signaling events in advanced glycation end product induced monocyte chemoattractant protein-1 expression in differentiated mouse podocytes. Nephrol. Dial. Transplant. 21 (2006) 299-313
15. Chuang P.Y., et al. Advanced glycation endproducts induce podocyte apoptosis by activation of the FOXO4 transcription factor. Kidney Int. 72 (2007) 965-976
16. Ruster C., et al. Angiotensin II upregulates RAGE expression on podocytes: role of AT2 receptors. Am. J. Nephrol. 29 (2009) 538-550
17. Pala L., et al. Vascular endothelial growth factor receptor-2 and low affinity VEGF binding sites on human glomerular endothelial cells: biological effects and advanced glycosylation end products modulation. Microvasc. Res. 70 (2005) 179-188
18. Ishihara K., et al. The receptor for advanced glycation end-products (RAGE) directly binds to ERK by a D-domain-like docking site. FEBS Lett. 550 (2003) 107-113
19. Hudson B.I., et al. Interaction of the RAGE cytoplasmic domain with diaphanous-1 is required for ligand-stimulated cellular migration through activation of Rac1 and Cdc42. J. Biol. Chem. 283 (2008) 34457-34468
20. Wang L., et al. Receptor for advanced glycation end products (RAGE) mediates neuronal differentiation and neurite outgrowth. J. Neurosci. Res. 86 (2008) 1254-1266
21. Lu T.C., et al. HIV-1 Nef disrupts the podocyte actin cytoskeleton by interacting with diaphanous interacting protein. J. Biol. Chem. 283 (2008) 8173-8182
22. Whaley-Connell A., et al. Diabetes mellitus and CKD awareness: the Kidney Early Evaluation Program (KEEP) and National Health and Nutrition Examination Survey (NHANES). Am. J. Kidney Dis. 53 (2009) S11-S21
23. Flyvbjerg A., et al. Long-term renal effects of a neutralizing RAGE antibody in obese type 2 diabetic mice. Diabetes 53 (2004) 166-172
24. Jensen L.J., et al. Renal effects of a neutralizing RAGE-antibody in long-term streptozotocin-diabetic mice. J. Endocrinol. 188 (2006) 493-501
25. Myint K.M., et al. RAGE control of diabetic nephropathy in a mouse model: effects of RAGE gene disruption and administration of low-molecular weight heparin. Diabetes 55 (2006) 2510-2522
26. Breyer M.D. Stacking the deck for drug discovery in diabetic nephropathy: in search of an animal model. J. Am. Soc. Nephrol. 19 (2008) 1623-1624
27. Breyer M.D., et al. Diabetic nephropathy: of mice and men. Adv. Chronic Kidney Dis. 12 (2005) 128-145
28. Inagi R., et al. A severe diabetic nephropathy model with early development of nodule-like lesions by megsin overexpression in RAGE/iNOS transgenic mice. Diabetes 55 (2006) 356-366
29. Zhao H.J., et al. Endothelial nitric oxide synthase deficiency produces accelerated nephropathy in mice. J. Am. Soc. Nephrol. 17 (2006) 2664-2669
30. Nakagawa T., et al. Diabetic endothelial nitric oxide synthase knockout mice develop advanced diabetic nephropathy. J. Am. Soc. Nephrol. 18 (2007) 539-550
31. Goldin A., et al. Blockade of receptor for advanced glycation end-products restores effective wound healing in diabetic mice. Circulation 114 (2006) 597-605
32. Kosugi T., et al. Lowering blood pressure blocks mesangiolysis and mesangial nodules, but not tubulointerstitial injury, in diabetic eNOS knockout mice. Am. J. Pathol. 174 (2009) 1221-1229
33. Zheng S., et al. Development of late-stage diabetic nephropathy in OVE26 diabetic mice. Diabetes 53 (2004) 3248-3257
34. Teiken J.M., et al. Podocyte loss in aging OVE26 diabetic mice. Anat. Rec. 291 (2008) 114-121
35. Powell D.W., et al. Renal tubulointerstitial fibrosis in OVE26 type 1 diabetic mice. Nephron Exp. Nephrol. 111 (2009) e11-e19
36. Zheng S., et al. Podocyte-specific overexpression of the antioxidant metallothionein reduces diabetic nephropathy. J. Am. Soc. Nephrol. 19 (2008) 2077-2085
37. Hou F.F., et al. Enhanced expression of receptor for advanced glycation endproducts in chronic kidney disease. J. Am. Soc. Nephrol. 15 (2004) 1889-1896
38. Rodriguez-Ayala E., et al. Enhanced RAGE-mediated NFkappaB stimulation in inflamed hemodialysis patients. Atherosclerosis 180 (2005) 333-340
39. Rudofsky Jr. G., et al. A 63 bp deletion in the promoter of RAGE correlates with a decreased risk for nephropathy in patients with type 2 diabetes. Exp. Clin. Endocrinol. Diabetes 112 (2004) 135-141
40. Prevost G., et al. Polymorphisms of the receptor for advanced glycation endproducts (RAGE) and the development of nephropathy in type 1 diabetic patients. Diabetes Metab. 31 (2005) 35-39
41. Lindholm E., et al. The -374 T/A polymorphism in the gene encoding RAGE is associated with diabetic nephropathy and retinopathy in type 1 diabetic subjects. Diabetologia 49 (2006) 2745-2755
42. Kankova K., et al. Haplotype analysis of the RAGE gene: identification of a haplotype marker for diabetic nephropathy in type 2 diabetes mellitus. Nephrol. Dial. Transplant 20 (2005) 1093-1102
43. Matsunaga-Irie S., et al. Relation between development of nephropathy and the p22phox C242T and receptor for advanced glycation end product G1704T gene polymorphisms in type 2 diabetic patients. Diabetes Care 27 (2004) 303-307
44. Yonekura H., et al. Roles of the receptor for advanced glycation endproducts in diabetes-induced vascular injury. J. Pharmacol. Sci. 97 (2005) 305-311
45. Hudson B.I., et al. Identification, classification, and expression of RAGE gene splice variants. FASEB J. 22 (2008) 1572-1580
46. Kalea A.Z., et al. Alternative splicing of the murine receptor for advanced glycation end-products (RAGE) gene. FASEB J. 23 (2009) 1766-1774
47. Raucci A., et al. A soluble form of the receptor for advanced glycation endproducts (RAGE) is produced by proteolytic cleavage of the membrane-bound form by the sheddase a disintegrin and metalloprotease 10 (ADAM10). FASEB J. 22 (2008) 3716-3727
48. Humpert P.E., et al. Soluble RAGE but not endogenous secretory RAGE is associated with albuminuria in patients with type 2 diabetes. Cardiovasc. Diabetol. 6 (2007) 9
49. Grossin N., et al. Severity of diabetic microvascular complications is associated with low soluble RAGE level. Diabetes Metab. 34 (2008) 393-395
50. Gohda T., et al. Increased serum endogenous secretory receptor for advanced glycation endproducts (esRAGE) levels in type 2 diabetic patients with decreased renal function. Diabetes Res. Clin. Pract. 81 (2008) 196-201
51. Kalousova M., et al. Soluble receptor for advanced glycation end products in patients with decreased renal function. Am. J. Kidney Dis. 47 (2006) 406-411
52. Kankova K., et al. Soluble RAGE, diabetic nephropathy and genetic variability in the AGER gene. Arch. Physiol. Biochem. 114 (2008) 111-119
53. Forbes J.M., et al. Modulation of soluble receptor for advanced glycation end products by angiotensin-converting enzyme-1 inhibition in diabetic nephropathy. J. Am. Soc. Nephrol. 16 (2005) 2363-2372
54. Chen Y., et al. Blockade of late stages of autoimmune diabetes by inhibition of the receptor for advanced glycation endproducts. J. Immunol. 173 (2004) 1399-1405
55. Moser B., et al. Blockade of RAGE suppresses alloimmune reactions in vitro and delays allograft rejection in murine heart transplantation. Am. J. Transplant. 7 (2007) 293-302
56. Moser B., et al. RAGE expression on T cells contributes to antigen-specific cellular expansion in vivo. J. Immunol. 179 (2007) 8051-8058
57. Chen Y., et al. RAGE ligation affects T cell activation and controls T cell differentiation. J. Immunol. 181 (2008) 4272-4278
58. Tian J., et al. Toll-like receptor 9-dependent activation by DNA-containing immune complexes is mediated by HMGB1 and RAGE. Nat. Immunol. 8 (2007) 487-496
59. Cataldegirmen G., et al. RAGE limits regeneration after massive liver injury by coordinated suppression of TNF-alpha and NF-kappa B. J. Exp. Med. 201 (2005) 473-484
60. Dumitriu I.E., et al. Requirement of HMGB1 and RAGE for the maturation of human plasmacytoid dendritic cells. Eur. J. Immunol. 35 (2005) 2184-2190
61. Yang D., et al. High mobility group box 1 protein induces the migration and activation of human dendritic cells and acts as an alarmin. J. Leukoc. Biol. 81 (2007) 59-66
62. Dumitriu I.E., et al. The secretion of HMGB1 is required for the migration of maturing dendritic cells. J. Leukoc. Biol. 81 (2007) 84-91
63. Manfredi A.A., et al. Maturing dendritic cells depend on RAGE for in vivo homing to lymph nodes. J. Immunol. 180 (2008) 2270-2275
64. Matsunaga N., et al. Advanced glycation end product is implicated in amyloid-related kidney complications. Scand. J. Clin. Lab. Invest. 65 (2005) 263-271
65. Liliensiek B., et al. Receptor for advanced glycation end products (RAGE) regulates sepsis but not the adaptive immune response. J. Clin. Invest. 113 (2004) 1641-1650
66. Lutterloh E.C., et al. Inhibition of the RAGE products increases survival in experimental models of severe sepsis and systemic infection. Crit. Care 11 (2007) R122
67. Hou F.F., et al. beta(2) microglobulin modified with advanced glycation endproducts delays monocyte apoptosis. Kidney Int. 59 (2001) 990-1002
68. Uesugi N., et al. Glycoxidative modification of AA amyloid deposits in renal disease. Nephrol. Dial. Transplant. 15 (2000) 355-365
69. Neal C.R., et al. Three dimensional reconstruction of glomeruli by electron microscopy reveals a distinct restrictive urinary subpodocyte space. J. Am. Soc. Nephrol. 16 (2005) 1223-1235
70. Salmon A.H.J., et al. New aspects of glomerular filtration barrier structure and function: five layers (at least), not three. Curr. Opin. Nephrol. Hypertens. 18 (2009) 197-205